

Mouse MIP-3α Immunoassay

Catalog Number: EA800165

For the quantitative determination of mouse MIP-3 α concentrations in cell culture supernates, serum, and plasma.

For research use only. Not for use in diagnostic procedures.

MANUFACTURED AND DISTRIBUTED BY:

OriGene Technologies,Inc.

9620 Medical Center Drive Suite 200 Rockville, MD 20850,USA

Tel: 1-301-340-3188 Fax: 301-340-9254 Mail: techsupport@origene.com Web: www.origene.com



TABLE OF CONTENTS

SECTION	PAGE	
BACKGROUND		1
PRINCIPLE OF THE ASSAY		1
TECHNICAL HINTS AND LIMITATIONS		2
PRECAUTIONS		2
KIT COMPONENTS& STORAGE CONDITIONS		3
OTHER SUPPLIES REQUIRED BUT NOT SUPP	LIED	.4
SPECIMEN COLLECTION & STORAGE		,4
REAGENTS PREPARATION		4
ASSAY PROCEDURE		.6
CALCULATION OF RESULTS		6
PERFORMANCE CHARACTERISTICS		8
REFERENCES	1	0




BACKGROUND

Mouse MIP- 3α , otherwise known as CCL20, LARC, and Exodus, is an 8 kDa protein belonging to the β-, or CC chemokine sub-family. It is synthesized as a 97 amino acid (aa) precursor that contains a 27 aa signal sequence plus a 70 aa mature segment. Mature mouse MIP-3α contains no potential N-linked glycosylation sites. Although human MIP-3α is suggested to contain an O-linked ribose, rodent MIP-3α does not contain any proline rich motifs that might indicate glycosylation. MIP- 3α is known to exist in multiple isoforms. An alternate splice form lacking the N-terminal alanine exists in both mouse and human. In addition, human MIP-3α apparently undergoes proteolytic processing at the C-terminus to generate peptides that are shorter by one, three, and six amino acid (aa) residues. All isoforms are equally bioactive. It is possible that mouse MIP- 3α may be processed similarly. The mature region of mouse MIP-3α shares 73% and 70% aa sequence identity with mature rat and human MIP- 3α , respectively. Among mouse β -chemokines, MIP- 3α is distantly related to MIP- 3β sharing 34% aa sequence identity. Cells known to express MIP-3α include monocytes, macrophages, microglia and astrocytes, mast cells, neutrophils, keratinocytes, intestinal epithelium, osteoblasts, fibroblasts, and endothelial cells.

PRINCIPLE OF THE ASSAY

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for MIP-3 α has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any MIP-3 α present is captured by the coated antibody after incubation. Following extensive washing, a biotin-conjugate antibody specific for MIP-3 α is added to detect the captured MIP-3 α protein in sample. For signal development, horseradish peroxidase (HRP)-conjugated Streptavidin is added, followed by tetramethyl-benzidine (TMB) reagent. Following a wash to remove any unbound combination, and enzyme conjugate is added to the wells. Solution containing sulfuric acid is used to stop color development and the color intensity which is proportional to the quantity of bound protein is measurable at 450nm.

Schematic diagram:





- 1. This ELISA should not be used beyond the expiration data on the kit label.
- 2. To avoid cross-contamination, use a fresh reagent reservoir and pipette tips for each step.
- 3. To ensure accurate results, some details, such as technique, plasticware and water sources should be emphasized.
- 4. A thorough and consistent wash technique is essential for proper assay performance.
- 5. A standard curve should be generated for each set of samples assayed.
- 6. It is recommended that all standards and samples be assayed in duplicate.
- 7. Avoid microbial contamination of reagents and buffers. Buffers containing protein should be made under aseptic conditions and be prepared fresh daily.
- 8. In order to ensure the accuracy of the results, the standard curve should be made every time.

PRECAUTIONS

The Stop Solution suggested for use with this kit is an acid solution. Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling.

KIT COMPONENTS& STORAGE CONDITIONS

DADT	SIZE	STORAGE	OF	OPENED/
PART	SIZE	RECONSTITU	TED MATI	ERIAL



Microwell Plate - antibody coated 96-well Microplate (8 wells ×12 strips)	1 plate	Return unused wells to the foil pouch containing the desiccant pack. Reseal along entire edge of the zip-seal. May be stored for up to 1 month at 2 – 8°C**	
Standard -lyophilized,2000 pg/vial upon reconstitution	2 vials	Aliquot and Store at -20°C** for six months	
Concentrated Biotin-Conjugated antibody(100X) - 120 ul/vial	1 vial	Store at 2-8°C **for six months	
Concentrated Streptavidin-HRP solution(100X) - 120 ul/vial	1 vial	Store at 2-8°C** for six months	
Standard /Sample Diluent - 16 ml/vial	1 bottle	Store at 2-8°C** for six months	
Biotin-Conjugate antibody Diluent - 16 ml/vial	1 bottle	Store at 2-8°C** for six months	
Streptavidin-HRP Diluent - 16 ml/vial	1 bottle	Store at 2-8°C** for six months	
Wash Buffer Concentrate (20x) - 30 ml/vial	1 bottle	Store at 2-8°C** for six months	
Substrate Solution - 12 ml/vial	1 bottle	Store at 2-8°C** for six months	
Stop Solution - 12 ml/vial	1 bottle	Store at 2-8°C** for six months	
Plate Cover Seals	4 pieces		

^{**}Provided this is within the expiration date of the kit.

OTHER SUPPLIES REQUIRED BUT NOT SUPPLIED

- 1. Microplate reader capable of measuring absorbance at 450 nm.
- 2. Pipettes and pipette tips.
- 3. Deionized or distilled water.



- 4. Squirt bottle, manifold dispenser, or automated microplate washer.
- 5. 500 mL graduated cylinder.

SPECIMEN COLLECTION & STORAGE

Cell Culture Supernates - Centrifuge cell culture media at $1000 \times g$ to remove debris. Assay immediately or aliquot and store samples at \leq -20 °C. Avoid repeated freezethaw cycles.

Serum - Use a serum separator tube (SST) and allow samples to clot for 2 hours at room temperature or overnight at 2-8°C. Centrifuge approximately for 15 minutes at $1000 \times g$. Assay immediately or aliquot and store samples at \leq -20 °C. Avoid repeated freeze-thaw cycles.


Plasma - Collect plasma using EDTA, heparin, or citrate as an anticoagulant. Centrifuge for 15 minutes at $1000 \times g$ within 30 minutes of collection. Assay immediately or aliquot and store samples at \leq -20 °C. Avoid repeated freeze-thaw cycles.

Note: The normal mouse serum or plasma samples are suggested to make a 1:2 dilution.

REAGENTS PREPARATION

- **1. Temperature returning** Bring all kit components and specimen to room temperature (20-25°C) before use.
- **2. Wash Buffer** Dilute 30mL of Wash Buffer Concentrate with 570mL of deionized or distilled water to prepare 600mL of Wash Buffer. If crystals have formed in the concentrate Wash Buffer, warm to room temperature and mix gently until the crystals have completely dissolved.
- 3. Standard/Specimen Reconstitute the Standard with 1.0mL of Standard/Sample Diluent. This reconstitution produces a stock solution of 2000 pg/mL. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions. Pipette 500μL of Standard/ Sample Diluent into 1000pg/ml tube and the remaining tubes. Use the stock solution of 2000pg/mL to produce a 2-fold dilution series (below). Mix each tube thoroughly and change pipette tips between each transfer. The 1000 pg/mL standard serves as the high standard. The Standard/ Sample Diluent serves as the zero standard (0 pg/mL).





Preparation of MIP-3α standard dilutions

- *If you do not run out of re-melting standard, store it at -20°C. Diluted standard shall not be reused.
- **4. Working solution of Biotin-Conjugate anti-mouse MIP-3α antibody:** Make a 1:100 dilution of the concentrated Biotin-Conjugate solution with the Biotin-Conjugate antibody Diluent in a clean plastic tube.
 - *The working solution should be used within one day after dilution.
- **5. Working solution of Streptavidin-HRP**: Make a 1:100 dilution of the concentrated Streptavidin-HRP solution with the Streptavidin-HRP Diluent in a clean plastic tube.
 - *The working solution should be used within one day after dilution.

ASSAY PROCEDURE

Prepare all reagents and standards as directed. Wash the plate 3 times before assay.



Add 100µl standard or samples to each well, incubate 90 minutes, 37°C.

Aspirate and wash 4 times

Add 100 μ l working solution of Biotin-Conjugate anti-mouse MIP-3 α antibody to each well, incubate 60 minutes,37°C.

 \prod Aspirate and wash 4 times

Add 100µl working solution of Streptavidin-HRP to each well, incubate 30 minutes,37°C.

 \square Aspirate and wash 5 times

Add 100µl Substrate solution to each well, incubate 15 minutes, 37°C. Protect from light.

IJ

Add 50µl Stop solution to each well. Read at 450nm within 5 minutes.

CALCULATION OF RESULTS


- 1. The standard curve is used to determine the amount of specimens.
- First, average the duplicate readings for each standard, control, and sample. All O.D. values are subtracted by the mean value of blank control before result interpretation.
- 3. Construct a standard curve by reducing the data using computer software capable of generating a four parameter logistic (4-PL) curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph.
- 4. The data may be linearized by plotting the log of the MIP-3 α concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.
- 5. This standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed.

Typical data using the MIP-3α ELISA

Standard(pg/ ml)	OD.	OD.	Average	Corrected
0	0.046	0.044	0.045	-
15.625	0.228	0.220	0.224	0.179
31.25	0.263	0.254	0.258	0.213



62.5	0.391	0.378	0.384	0.339
125	0.621	0.600	0.610	0.565
250	1.008	0.974	0.991	0.946
500	1.642	1.586	1.614	1.569
1000	2.675	2.584	2.629	2.584



Representative standard curve for MIP-3α ELISA.

Performance Characteristics

SENSITIVITY: The minimum detectable dose was 8pg/mL.

SPECIFICITY: This assay recognizes both natural and recombinant mouse MIP- 3α . The factors listed below were prepared at 100 ng/ml in Standard /sample Diluent and assayed for cross-reactivity and no significant cross-reactivity or interference was



Factors assayed for cross-reactivity

Recombinant mouse	Recombinant rat	Recombinant human
6Ckine		MIP-3α
C10		MIP-3β
CCL28		
CTACK		
Eotaxin		
MIP-1α		
MIP-1β		

REPEATABILITY: The coefficient of variation of both intra-assay and inter-assay were less than 10%.

RECOVERY: The recovery of MIP-3 α spiked to three different levels in four samples throughout the range of the assay in various matrices was evaluated.

Recovery of MIP-3α in two matrices

Sample Type	Average % of Expected Range (%)	Range (%)
Citrate plasma	92	85-99
Cell culture supernatants	108	98-118

LINEARITY: To assess the linearity of the assay, three samples were spiked with high concentrations of MIP-3 α in various matrices and diluted with the appropriate Sample Diluent to produce samples with values within the dynamic range of the assay. (The plasma samples were initially diluted 1:1)

Dilution ratio	Recovery (%)	Citrate plasma	Cell culture supernatants
1:2	Average% of Expected	97	102



	Range (%)	88-100	94-110
1.4	Average% of Expected	96	104
1:4 Range (%)		87-105	97-112
1:8	Average% of Expected	96	103
1.0	Range (%)	88-103	94-114
1.16	Average% of Expected	98	106
1:16	Range (%)	89-109	95-115

REFERENCES

- 1. Zlotnik, A. and O. Yoshie (2000) Immunity 12:121. Miller, M.D. et al. (1990) J. Immunol. 145:2737.
- 2. Yoshie, O. et al.(1997) J. Leukoc. Biol. 62:634.
- 3. Zlotnik, A. et al.(1999) Crit. Rev. Immunol. 19:1.
- 4. Rot, A. and U.H. von Andrian (2004) Annu. Rev. Immunol. 22:891.
- 5. Varona, R. et al.(1998) FEBS Lett. 440:188.
- 6. Schutyser, E. et al.(2000) J. Immunol. 165:4470.



7. Tanaka, Y. et al.(1999) Eur. J. Immunol. 29:633.8. Nelson, R.T. et al.(2001)

Genomics 7:28.

- 8. Utans-Schneitz, U. et al.(1998) J. Neuroimmunol. 92:179.
- 9. Utans-Schneitz, U. et al. (1998) J. Neuroimmunol. 92:179.
- 10. Hieshima, K. et al. (1997) J. Biol. Chem. 272:5846.
- 11. Hromas, R. et al. (1997) Blood 89:3315.
- 12. Rossi, D.L. et al. (1997) J. Immunol. 158:1033.
- 13. Ngo, V.N. et al. (1998) J. Exp. Med. 188:181.
- 14. Lin, T-J. et al. (2003) Inf. Immun. 71:365.
- 15. Akashoshi, T. et al. (2003) Inf. Immun. 71:524.
- 16. Nakayama, T. et al. (2001) Int. Immunol. 13:95.
- 17. Schmuth, S. et al. (2002) Exp. Dermatol. 11:135.
- 18. Fujiie, S. et al. (2001) Int. Immunol. 1:1255.
- 19. Izadpanah, A. et al. (2001) Am. J. Physiol. Gastrointest. Liver Physiol. 280:G710.
- 20. Fleming, M.D. et al. (2003) Blood 101:2473.